Europe Sickle Cell Disease Treatment Market Size, Share & Industry Trends Analysis Report By Treatment (Blood Transfusion, Pharmacotherapy, and Bone Marrow Transplant), By End-Use (Hospitals, Specialty Clinics), By Country and Growth Forecast, 2023 - 2030

The Europe Sickle Cell Disease Treatment Market should witness market growth of 27.4% CAGR during the forecast period (2023-2030).

The sickled cells that give the illness its name can cause severe damage to organs like the heart and kidneys, as well as pain throughout the body. Mild to moderate anemia is frequently present in people with sickle cell disease. However, they may get severe anemia, which is considered fatal.

Red blood cells are constantly in short supply because sickle cells expire prematurely. They likewise become caught and obstruct the flow of blood as they pass through tiny blood arteries. This may result in discomfort as well as more severe health issues like an infection, acute chest syndrome, and stroke. SCD comes in a variety of forms. A person's particular form of SCD is determined by the genes they acquired from their parents. Genes that encode defective hemoglobin are inherited by people with SCD.

Throughout the region, millions of people suffer with sickle cell disease. Hemoglobin gene mutations can result in genotypic and phenotypic variations of sickle cell anemia. Throughout the forecast period, the market expansion is anticipated to be driven by the condition's high frequency and the ailment's rising severity.

According to the National Institute for Health and Care Excellence (NICE), there are currently 12,500-15,000 people in England who have sickle cell disease, and according to data from NHS Digital, there were 24,573 hospital admissions in England in 2020-2021 where sickle cell disorders were the primary diagnosis. The average age of these hospitalizations was 29 years, and 35% were emergency admissions. One-fourth of those who were admitted were under the age of 18. Hence, with rise in the occurrence of disease, the market is estimated to grow.

The Germany market dominated the Europe Sickle Cell Disease Treatment Market by Country in 2022; thereby, achieving a market value of $482.7 Million by 2030. The UK market is exhibiting a CAGR of 26.3% during (2023-2030). Additionally, The France market would experience a CAGR of 28.3% during (2023-2030).

Based on Treatment, the market is segmented into Blood Transfusion, Pharmacotherapy, and Bone Marrow Transplant. Based on End-Use, the market is segmented into Hospitals, Specialty Clinics and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Novartis AG, Pfizer Inc., bluebird bio, Inc., CSL Limited, Emmaus Life Sciences, Inc., Bristol Myers Squibb Company, CRISPR Therapeutics AG, Agios Pharmaceuticals, Inc. (LES LABORATOIRES SERVIER SAS), Novo Nordisk A/S and Medunik USA (Duchesnay Inc.).

Scope of the Study

By Treatment

• Blood Transfusion
• Pharmacotherapy
• Bone Marrow Transplant

By End-Use

• Hospitals
• Specialty Clinics
• Others

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Novartis AG
• Pfizer Inc.
• bluebird bio, Inc.
• CSL Limited
• Emmaus Life Sciences, Inc.
• Bristol Myers Squibb Company
• CRISPR Therapeutics AG
• Agios Pharmaceuticals, Inc. (LES LABORATOIRES SERVIER SAS)
• Novo Nordisk A/S
• Medunik USA (Duchesnay Inc.)

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free